Roche Aims to Capitalize on Obesity-Drug Market as It Seeks Recovery Amid Sector Turmoil

  • 📰 IrishTimes
  • ⏱ Reading Time:
  • 20 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 35%
  • Publisher: 98%

Business And Finance 뉴스

Roche,Obesity Drugs,Carmot Acquisition

Swiss pharmaceutical giant Roche is making a major move in the obesity-drugs market by acquiring Carmot for up to $3.1 billion. The company hopes this acquisition will help it regain a leading position in an area expected to grow to $200 billion by 2031, following a period of decline.

Investors who have been enduring a turbulent ride since Malin's flotation in March 2015, now face a potential end to the uncertainty as Roche eyes a recovery in the obesity-drugs market. Roche, previously underperforming and grappling with declining sales of its COVID-19 test kits and drug candidate failures, has made a significant move this year by acquiring Carmot for up to $3.1 billion.

This acquisition comes as the obesity-drugs market is projected to grow significantly, reaching an estimated $200 billion by 2031. The wider pharmaceutical sector, meanwhile, has been dealing with the repercussions of Donald Trump's re-election and the proposed appointment of an anti-vaccine activist as his health secretary, which has led to a further downturn in stock prices

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 3. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Malin Corporation Shares Jump 37% on Roche Acquisition of PoseidaMalin Corporation, a Dublin-based life sciences investment firm, experienced a significant rise in its share price following the news that Roche, a Swiss pharmaceuticals giant, has agreed to acquire Poseida, a Nasdaq-listed biopharma company in which Malin holds a 12% stake, for up to $1.5 billion.
출처: IrishTimes - 🏆 3. / 98 더 많은 것을 읽으십시오 »